Obstructive sleep apnea (OSA): Clinical trials of tirzepatide showed significant improvement of OSA
These outcomes positioned Mounjaro among the most effective prescription obesity treatments studied so far
INTRODUCTION Tirzepatide is a synthetic peptide composed of 39 amino acids, which functions as a dual receptor agonist (RA) binding both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors and this unique mechanism of action resulted in the nickname twincretin. The structure of tirzepatide is based on that of the native GIP with the addition of a 20-carbon fatty diacid moiety, which increases its half-life to 5 days allowing for once-weekly administration.1 Studies using animal models of obesity and diabetes have shown that the co-administration of GIP and GLP-1 has synergistic effects in reducing body weight, food consumption, and fat mass.1 Tirzepatides dual agonist activity may result in these benefits in humans as well, as evidenced the significant reductions in glycated hemoglobin (HbA1c) levels and body weight in patients with type 2 diabetes mellitus (T2DM) observed in phase 3 clinical trials (such as, SURPASS
If you are concerned about stomach irritation or kidney health, you may want to consider alternatives to ibuprofen
Individual results vary based on dosage, adherence, diet, and exercise
In retatrutide's design, this risk is counterbalanced by the co-activation of GLP-1R and GIPR, which drive insulin secretion and suppress glucagon
_03.jpg)
